B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 166.05 DKK -0.78% Market Closed
Market Cap: 13.1B DKK
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one BAVA stock under the Base Case scenario is 225.86 DKK. Compared to the current market price of 166.05 DKK, Bavarian Nordic A/S is Undervalued by 26%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BAVA Relative Value
Base Case
225.86 DKK
Undervaluation 26%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

2.1
P/S
P/S
Price to Sales
2.1
vs History
84
vs Industry
79
Median 3Y
2.8
Median 5Y
5.9
Industry
7.3
Forward
2.3
More Details
11.6
P/E
P/E
Price to Earnings
11.6
vs History
47
vs Industry
9
Median 3Y
11.4
Median 5Y
11.4
Industry
21.6
Forward
15.7
More Details
8.2
P/OCF
P/OCF
Price to OCF
8.2
vs History
52
vs Industry
12
Median 3Y
8.2
Median 5Y
9.6
Industry
19.8
More Details
56.3
P/FCFE
P/FCFE
Price to FCFE
56.3
vs History
7
vs Industry
8
Median 3Y
-8.1
Median 5Y
-8.7
Industry
24.9
More Details
1.2
P/B
P/B
Price to Book Value
1.2
vs History
87
vs Industry
53
Median 3Y
1.5
Median 5Y
1.9
Industry
2.4
More Details
1.8
EV/S
EV/S
Enterprise Value to Sales
1.8
vs History
87
vs Industry
70
Median 3Y
2.6
Median 5Y
5.5
Industry
7.4
Forward
2
More Details
3.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.5
vs History
79
vs Industry
64
Median 3Y
4.7
Median 5Y
16.4
Industry
9.3
More Details
6.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
6.4
vs History
57
vs Industry
11
Median 3Y
6.6
Median 5Y
7.8
Industry
3.9
Forward
7.2
More Details
9.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
9.8
vs History
42
vs Industry
8
Median 3Y
8.4
Median 5Y
8.4
Industry
3.7
Forward
12.2
More Details
7.1
EV/OCF
EV/OCF
Enterprise Value to OCF
7.1
vs History
52
vs Industry
13
Median 3Y
7.1
Median 5Y
8.4
Industry
4.9
More Details
40
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
40
vs History
12
vs Industry
8
Median 3Y
-8.6
Median 5Y
-10.4
Industry
3.2
More Details
1
EV/IC
EV/IC
Enterprise Value to IC
1
vs History
87
vs Industry
56
Median 3Y
1.2
Median 5Y
1.6
Industry
4.3
More Details

Multiples Across Competitors

BAVA Competitors Multiples
Bavarian Nordic A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Bavarian Nordic A/S
CSE:BAVA
13B DKK 2.1 11.6 6.4 9.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 329 482 -172 668.6 -209 674.7 -207 282.1
US
Abbvie Inc
NYSE:ABBV
378.6B USD 6.7 89.3 17.4 26.3
US
Amgen Inc
NASDAQ:AMGN
170.3B USD 5.1 41.6 16.7 29.6
US
Gilead Sciences Inc
NASDAQ:GILD
140B USD 4.9 291.7 11.4 14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
132B USD 12 -246.5 27 28.3
US
Epizyme Inc
F:EPE
94.1B EUR 1 939.2 -494.8 -538.8 -524.5
AU
CSL Ltd
ASX:CSL
120.6B AUD 5.1 28.1 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
74.4B USD 5.2 16.9 11.2 12.5
US
Seagen Inc
F:SGT
39.3B EUR 18.7 -57.3 -61.6 -55.6
NL
argenx SE
XBRU:ARGX
32.9B EUR 16.4 43.2 318.7 -2 348.3
P/S Multiple
Revenue Growth P/S to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average P/S: 3 302 863.4
2.1
-7%
N/A
FR
Pharnext SCA
OTC:PNEXF
36 329 482
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.1
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
12
10%
1.2
US
E
Epizyme Inc
F:EPE
1 939.2
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.2
7%
0.7
US
S
Seagen Inc
F:SGT
18.7
30%
0.6
NL
argenx SE
XBRU:ARGX
16.4
37%
0.4
P/E Multiple
Earnings Growth PEG
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average P/E: 74.6
11.6
-15%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -172 668.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
89.3
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.6
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
291.7
185%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -246.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -494.8 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.3 N/A N/A
NL
argenx SE
XBRU:ARGX
43.2
19%
2.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBITDA: 53.3
6.4
-16%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 674.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.4
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.7
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.4
6%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -538.8 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.2
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.6 N/A N/A
NL
argenx SE
XBRU:ARGX
318.7
168%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
B
Bavarian Nordic A/S
CSE:BAVA
Average EV/EBIT: 20.3
9.8
-18%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -207 282.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
26.3
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.6
31%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.3
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -524.5 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 348.3 N/A N/A

See Also

Summary
BAVA intrinsic value, competitors valuation, and company profile.
DCF Valuation
BAVA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BAVA stock valuation using valuation multiples.
Wall Street Estimates
BAVA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BAVA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 239,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.